-
1.发明申请公开(公告)号：US20190322672A1
公开(公告)日：2019-10-24
申请号：US16344459
申请日：2017-10-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Stephen T. Wrobleski , David S. Weinstein , Michael G. Yang
IPC: C07D487/04 , C07D471/04
Abstract: Compounds having the following formula (I), or a stereoisomer or pharmaceutically-acceptable salt thereof, where all substituents are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.
-
公开(公告)号：US10308652B2
公开(公告)日：2019-06-04
申请号：US15558708
申请日：2016-03-17
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Stephen T. Wrobleski , Gregory D. Brown , Shuqun Lin , Jingwu Duan , Zhonghui Lu , Murali T. G. Dhar , Hai-Yun Xiao , Andrew J. Tebben
IPC: C07D487/14 , C07D491/147 , A61K31/5025 , A61P37/00 , C07D471/14 , C07D487/06 , A61P29/00 , A61P27/00
Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is N; W is: —(CR3R3)2-5-, —(CR3R3)x-Y—(CR3R3)y-, —Y—(CR3R3)2-3-Y—, —CR3R3-Y—(CR3R3)2-Y—, —Y—(CR3R3)2-Y—CR3R3-; and Y, R1, R2, R3, R5, R6, R8, x, and y are define herein. Also disclosed are methods of using such compounds as modulators of TNFα, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
-
3.发明申请公开(公告)号：US20170209426A1
公开(公告)日：2017-07-27
申请号：US15480787
申请日：2017-04-06
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Ryan M. Moslin , David S. Weinstein , Stephen T. Wrobleski , Yanlei Zhang , John S. Tokarski , Michael E. Mertzman , Chunjian Liu
IPC: A61K31/455 , A61K31/506
CPC classification number: A61K31/455 , A61K31/44 , A61K31/444 , A61K31/506 , C07B59/002 , C07B2200/05 , C07D213/56 , C07D213/82 , C07D401/12 , C07D405/12 , C07D413/12 , C07D417/12
Abstract: Compounds having the following formula I: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα by acting on Tyk-2 to cause signal transduction inhibition.
-
公开(公告)号：US20220356180A1
公开(公告)日：2022-11-10
申请号：US17244938
申请日：2021-04-29
Applicant: Bristol-Myers Squibb Company
Inventor： Ryan M. Moslin , David S. Weinstein , Stephen T. Wrobleski , John S. Tokarski , Amit Kumar , Douglas G. Batt , Shuqun Lin , Chunjian Liu , Steven H. Spergel , Yanlei Zhang , Qingjie Liu
IPC: C07D417/14 , C07D403/12 , C07D401/14 , C07D413/14 , C07D401/12 , C07D237/24 , C07D403/14 , C07D413/12 , C07D417/12 , C07B59/00
Abstract: Compounds having the following formula I. or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.
-
5.发明申请ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFN ALPHA 有权用于调节IL-12，IL-23和/或IFNα的ALKYL酰胺取代的吡咯烷酮化合物公开(公告)号：US20150299139A1
公开(公告)日：2015-10-22
申请号：US14441213
申请日：2013-11-07
Applicant: Bristol-Myers Squibb Company
Inventor： Joseph B. Santella , Ryan M. Moslin , David S. Weinstein , Stephen T. Wrobleski , John S. Tokarski
IPC: C07D239/48
CPC classification number: C07D239/48 , C07D239/95
Abstract: Compounds having the following formula (I): or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα by acting on Tyk-2 to cause signal transduction inhibition.
Abstract translation: 具有下式（I）的化合物或其立体异构体或药学上可接受的盐，其中R 1，R 2，R 3，R 4和R 5如本文所定义，可用于调节IL-12，IL-23和/ 或通过作用于Tyk-2引起信号转导抑制的IFNα。
-
Patent Agency Ranking
公开(公告)号：US10781215B2
公开(公告)日：2020-09-22
申请号：US16344459
申请日：2017-10-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Stephen T. Wrobleski , David S. Weinstein , Michael G. Yang
IPC: C07D487/04 , C07D471/04 , C07D473/34
Abstract: Compounds having the following formula (I), or a stereoisomer or pharmaceutically-acceptable salt thereof, where all substituents are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.
-
公开(公告)号：US11021475B2
公开(公告)日：2021-06-01
申请号：US16687279
申请日：2019-11-18
Applicant: Bristol-Myers Squibb Company
Inventor： Ryan M. Moslin , David S. Weinstein , Stephen T. Wrobleski
IPC: C07D417/14 , C07D417/12 , C07B59/00 , C07D413/12 , C07D403/14 , C07D237/24 , C07D401/12 , C07D413/14 , C07D401/14 , C07D403/12
Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.
-
公开(公告)号：US10112944B2
公开(公告)日：2018-10-30
申请号：US15558724
申请日：2016-03-17
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Lawrence R. Marcin , Stephen T. Wrobleski , T.G. Murali Dhar
IPC: C07D471/14
Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is CR6 or N; W is: (i) —(CR3R3)1-4— or (ii) —(CR3R3)x-Y—(CR3R3)y-; and Y, R1, R2, R3, R5, R6, R7, x, and y are define herein. Also disclosed are methods of using such compounds as modulators of TNFα, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
-
9.发明授权公开(公告)号：US09987266B2
公开(公告)日：2018-06-05
申请号：US15480787
申请日：2017-04-06
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Ryan M. Moslin , David S. Weinstein , Stephen T. Wrobleski , Yanlei Zhang , John S. Tokarski , Michael E. Mertzman , Chunjian Liu
IPC: A61K31/455 , A61K31/506
CPC classification number: A61K31/455 , A61K31/44 , A61K31/444 , A61K31/506 , C07B59/002 , C07B2200/05 , C07D213/56 , C07D213/82 , C07D401/12 , C07D405/12 , C07D413/12 , C07D417/12
Abstract: Compounds having the following formula I: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα by acting on Tyk-2 to cause signal transduction inhibition.
-
10.发明授权公开(公告)号：US09663467B2
公开(公告)日：2017-05-30
申请号：US15034915
申请日：2014-01-16
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Ryan M. Moslin , David S. Weinstein , Stephen T. Wrobleski , Yanlei Zhang , John S. Tokarski , Michael E. Mertzman , Chunjian Liu
IPC: C07D213/56 , C07D405/12 , C07D401/12 , C07D213/82 , C07D413/12 , C07D417/12 , C07B59/00
CPC classification number: A61K31/455 , A61K31/44 , A61K31/444 , A61K31/506 , C07B59/002 , C07B2200/05 , C07D213/56 , C07D213/82 , C07D401/12 , C07D405/12 , C07D413/12 , C07D417/12
Abstract: Compounds having the following formula (I): or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα by acting on Tyk-2 to cause signal transduction inhibition.
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.026 seconds)
